Psychedelic-Assisted Therapy in Toronto and the GTA

Toronto and the Greater Toronto Area (GTA) have the largest concentration of private ketamine and Spravato providers in Canada. This guide explains how Toronto and GTA patients can access psychedelic-assisted therapy through ATMA CENA, what the CPSO regulatory framework requires, and how Ontario coverage pathways such as WSIB work.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

• ATMA CENA does not operate a corporate clinic in Toronto. ATMA CENA's corporate clinics are in Calgary and Edmonton. For Toronto and GTA patients, access runs through ATMA CENA's member-clinic network and the CoCare program.
• CoCare is the documented pathway for keeping your own therapist. Through CoCare, ATMA CENA can partner with your existing therapist if they have the appropriate training and build a service agreement with ATMA CENA.
• Toronto and the GTA have the largest concentration of private ketamine and Spravato providers in Canada. When you evaluate any clinic, focus on regulatory accreditation, medical staffing, and a structured preparation-and-integration model rather than headline pricing.
• CPSO regulatory framework: the Out-of-Hospital Premises Inspection Program (OHPIP) Level II applies to IV ketamine delivered in non-hospital settings, including deep-sedation credentialing.
• WSIB Ontario lists ketamine and esketamine with prior authorization across specialty formularies, making it the most-developed Canadian workers' compensation pathway for ketamine.
• First-responder PTSD: Ontario's 2016 Bill 163 established presumptive PTSD coverage for designated first responders; Bill 190 (Royal Assent October 28, 2024) extended it to wildland firefighters and wildland fire investigators.
• Psilocybin and MDMA are accessible in Ontario only through Health Canada's case-by-case pathway, initiated by a physician. ATMA CENA can support preparation and integration through CoCare.

If you are a Toronto or GTA patient evaluating psychedelic-assisted therapy, you can book a free 15-minute information call to discuss the GTA landscape and your access options with ATMA CENA's clinical team.

ATMA CENA in the GTA: honest framing

ATMA CENA's Canadian footprint includes corporate clinics in Calgary and Edmonton, plus a network of member clinics across the country. ATMA CENA does not operate a corporate clinic in Toronto. Here is how Toronto and GTA patients realistically access ATMA CENA:

• Member-clinic network. ATMA CENA's member-clinic network extends across the country, including Ontario and the GTA. To see which member clinics are currently listed near you, visit the member clinics page. Member clinics deliver care under ATMA CENA's preparation, medicine, and integration model.

• CoCare. For Toronto patients who want to keep their existing therapist, the CoCare program lets ATMA CENA partner with your current therapist if they have the appropriate training and build a service agreement with ATMA CENA. For Toronto proper, CoCare is the lead pathway.

We share this framing plainly because it matters to your planning. If you need care inside Toronto specifically, ATMA CENA does not operate a corporate clinic there; the honest options are the member-clinic network and CoCare.

What Toronto and the GTA offer across psychedelic-assisted therapy

Ketamine therapy

Ketamine is approved by Health Canada as an anaesthetic. Use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators (in Ontario, the College of Physicians and Surgeons of Ontario, CPSO).

Toronto and the GTA have the largest concentration of private ketamine providers in Canada, delivered through several formats: IV infusion clinics, intramuscular and sublingual ketamine-assisted psychotherapy clinics, and multi-substance psychiatric practices. Because the market is large and varied, the most useful thing you can do is learn how to evaluate a clinic rather than chase a single name. See How to evaluate a Toronto or GTA clinic below.

ATMA CENA's own ketamine-assisted therapy uses intranasal ketamine (including Spravato and compounded intranasal formulations), intramuscular ketamine, and oral ketamine. ATMA CENA does not provide IV ketamine infusion. For Toronto patients, this care is accessed through the member-clinic network or CoCare. For a plain-language breakdown of what ATMA CENA's ketamine-assisted therapy costs, see Ketamine Therapy Cost in Canada.

Spravato (intranasal esketamine)

Health Canada approved intranasal esketamine (Spravato) in May 2020, in combination with an SSRI or SNRI, for treatment-resistant major depressive disorder (TRD) in adults aged 18 to 64. Initiation in patients aged 65 or older is not recommended, and Spravato is not approved for PTSD.

GTA Spravato providers operate as Janssen Journey-certified clinics, and the Health Canada label requires in-clinic dosing supervision with a post-dose monitoring window. Spravato is often the most likely-covered psychedelic-assisted therapy product through private insurance prior authorization. Note that Canada's national drug-assessment body, CDA-AMC (formerly CADTH), issued a do-not-reimburse recommendation for Spravato for TRD on December 18, 2020, so public drug plans generally do not fund it.

Psilocybin

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada, on a case-by-case basis, and is not guaranteed. Access is primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness.

In the GTA, the medical request is initiated by a prescribing physician, not by ATMA CENA directly. ATMA CENA can support preparation and integration through CoCare once authorization is in place.

MDMA-assisted therapy

MDMA-assisted therapy operates under the same case-by-case Health Canada framework. Access is primarily granted for adults with PTSD, on a case-by-case basis, and is not guaranteed. Service-related PTSD is a common indication, but no public pathway funds MDMA-assisted therapy in Ontario at this time, and access still requires a prescribing physician to initiate the request. ATMA CENA can support preparation and integration through CoCare where authorization is in place.

Toronto and the GTA's regulatory framework

Federal

• Ketamine: Schedule I under the CDSA; Health Canada approved as an anaesthetic. Psychiatric use is off-label.
• Spravato: Health Canada approved for TRD in adults aged 18 to 64 in May 2020; not approved for PTSD.
• Psilocybin and MDMA: accessible only through Health Canada's case-by-case pathway, initiated by a physician; approval is not guaranteed.

Provincial: CPSO Ontario

• Out-of-Hospital Premises Inspection Program (OHPIP) Level II: required for IV ketamine in non-hospital settings, including deep-sedation credentialing.
• Broader psychedelic-assisted therapy oversight through CPSO standards.

Insurance and coverage

Coverage in Ontario is assessed case-by-case. The insurer or board adjudicates each claim; ATMA CENA's role is to support a complete, well-documented application, not to guarantee an outcome.

• WSIB Ontario: lists ketamine and esketamine with prior authorization across five specialty formularies (Psychotraumatic, Serious Injury, Musculoskeletal, CNS/PNS, and Chronic Pain Disability). This is the most-developed Canadian workers' compensation pathway for ketamine. Precise prior-authorization criteria are set by WSIB and can change over time.
• First-responder PTSD presumption: Ontario's 2016 Bill 163 (Supporting Ontario's First Responders Act, 2016) established presumptive PTSD coverage for designated first responders. Bill 190 (Working for Workers Five Act, 2024, Royal Assent October 28, 2024) extended this coverage to wildland firefighters and wildland fire investigators.
• PSHCP / Canada Life: Spravato coverage for federal public servants via prior authorization (Form M7520).
• Private insurance: Spravato is the psychedelic-assisted therapy product most likely covered, with prior authorization.
• VAC: Veterans Affairs Canada will consider funding the ketamine drug (ketamine infusion, oral ketamine, or Spravato) for treatment-resistant depression or as a co-existing condition with PTSD, and ketamine for chronic pain, when prescribed by a treating psychiatrist. VAC does not currently fund psychedelic-assisted psychotherapy, including ketamine-assisted psychotherapy (KAP), psilocybin, or MDMA-assisted therapy.
• ODB: Spravato is not on the standard Ontario Drug Benefit formulary; access is considered case-by-case through the Exceptional Access Program (EAP) via the SADIE portal.

How to evaluate a Toronto or GTA clinic

Because Toronto and the GTA have the largest concentration of private providers in Canada, your main task is choosing well. These neutral questions help you compare any clinic:

• Regulatory accreditation. For IV ketamine in a non-hospital setting, ask whether the premises holds CPSO OHPIP Level II accreditation and whether deep-sedation credentialing is in place.
• Medical oversight. Ask who supervises dosing, what their regulated title and registration are, and how medical emergencies are handled on site.
• Structured preparation and integration. Ask whether the program includes preparation and integration, not just dosing. Evidence-informed psychedelic-assisted therapy treats dosing as one phase of a larger process.
• Indication fit. Ask whether the clinic treats your specific indication and how it screens for contraindications.
• Cost transparency and coverage support. Ask for the full cost in writing and whether the clinic will help document a WSIB, VAC, or private-insurer application.
• Continuity of care. Ask how the clinic coordinates with your existing therapist or family physician.

If you want help working through these questions, you can book a free 15-minute information call with ATMA CENA's clinical team.

Local Toronto and GTA practical notes

• Population: Toronto is Canada's largest metropolitan area, and the broader GTA is home to several million residents.
• Major hospitals: Toronto General Hospital, Mount Sinai Hospital, St. Michael's Hospital, Sunnybrook Health Sciences Centre, North York General Hospital, and multiple community hospitals.
• Universities: University of Toronto, York University, and Toronto Metropolitan University, among others.
• Health authority: Ontario Health (regional structure).
• Transit: TTC subway and bus; GO Transit (Lakeshore West connects Mississauga and Port Credit; other lines connect Hamilton and beyond); UP Express.
• Catchment: downtown Toronto, Scarborough, Etobicoke, North York, York, and East York; the broader GTA includes Mississauga, Brampton, Hamilton, Vaughan, Markham, Richmond Hill, Pickering, and Oakville.
• First-responder workforce: Toronto Police Service, Toronto Paramedic Services, Toronto Fire Services, the Ontario Provincial Police, and large hospital nursing populations make up a substantial workforce eligible under Ontario's first-responder PTSD presumption.
• Federal workforce: smaller than Ottawa but a meaningful PSHCP-eligible population.
• Post-session: a 24-hour no-driving rule applies after ketamine or Spravato dosing; TTC, GO Transit, and rideshare are practical alternatives.

How to start

A realistic Toronto and GTA pathway:

1. Identify your indication and treatment history.
2. Map to a substance pathway: ketamine (off-label, the most broadly accessible); Spravato (Health Canada-approved for TRD in adults 18 to 64); psilocybin (case-by-case Health Canada access); MDMA-assisted therapy (case-by-case Health Canada access).
3. Map to a coverage pathway: WSIB Ontario for compensable conditions, PSHCP for federal public servants, VAC for the ketamine drug for veterans, or private prior authorization for Spravato. Each is adjudicated case-by-case.
4. Map to a provider: ATMA CENA's member-clinic network for the preparation, medicine, and integration model, or CoCare for Toronto patients who keep their existing therapist. Use the evaluation questions above when comparing any other clinic.
5. Book the ATMA CENA information call.

Ready to map your options? Book a free 15-minute information call and ATMA CENA's clinical team will walk through your Toronto or GTA pathway, including member-clinic and CoCare access.

Frequently asked questions

Is there an ATMA CENA corporate clinic in Toronto?

No. ATMA CENA's corporate clinics are in Calgary and Edmonton. For Toronto and GTA patients, access runs through ATMA CENA's member-clinic network and the CoCare program. Through CoCare, ATMA CENA can partner with your existing therapist if they have the appropriate training and build a service agreement with ATMA CENA.

How should I evaluate a ketamine clinic in Toronto or the GTA?

Focus on regulatory accreditation (CPSO OHPIP Level II for IV ketamine in non-hospital settings), medical oversight and staffing, whether the program includes structured preparation and integration rather than dosing alone, fit for your indication, written cost and coverage support, and how the clinic coordinates with your existing care. Toronto and the GTA have the largest concentration of private providers in Canada, so comparing on these factors matters more than any single name.

Can I use my WSIB coverage for ketamine?

WSIB Ontario lists ketamine and esketamine with prior authorization across specialty formularies, the most-developed workers' compensation pathway for ketamine in Canada. Coverage is adjudicated case-by-case for compensable injuries; WSIB decides, and ATMA CENA supports the application. Ontario's 2016 Bill 163 presumptive PTSD legislation can support eligibility for designated first responders, and Bill 190 (October 28, 2024) extended that presumption to wildland firefighters and wildland fire investigators.

Can my Toronto-area first-responder coverage support MDMA-assisted therapy?

WSIB Ontario does not list MDMA on its workers' compensation formularies. The realistic WSIB-covered PTSD medication pathway in 2026 is ketamine. MDMA-assisted therapy in Ontario is accessible only through Health Canada's case-by-case pathway, initiated by a physician, and is not funded by WSIB.

Is psilocybin therapy available in Toronto?

Only through Health Canada's case-by-case pathway. Approval is granted case-by-case and is not guaranteed; access is primarily granted for adults with treatment-resistant depression or distress associated with a life-threatening illness. A prescribing physician initiates the request. ATMA CENA can support preparation and integration through CoCare once authorization is in place.

What about Hamilton or other GTA cities?

ATMA CENA's member-clinic network includes locations across Ontario. You can review current listings on the member clinics page.

What if I'm a Toronto veteran?

Veterans Affairs Canada will consider funding the ketamine drug (ketamine infusion, oral ketamine, or Spravato) for treatment-resistant depression or as a co-existing condition with PTSD, and ketamine for chronic pain, when prescribed by a treating psychiatrist. VAC does not currently fund psychedelic-assisted psychotherapy, including KAP, psilocybin, or MDMA-assisted therapy; veterans pursuing those through Health Canada's case-by-case pathway pay out-of-pocket.

What about Spravato in Toronto?

GTA Spravato providers operate as Janssen Journey-certified clinics. Spravato is Health Canada-approved for TRD in adults aged 18 to 64 and is not approved for PTSD. It is the psychedelic-assisted therapy product most likely covered through private insurance prior authorization; federal public servants have a PSHCP / Canada Life pathway via Form M7520.

Can I do psilocybin therapy through ODB?

Generally no. Spravato is not on the standard Ontario Drug Benefit formulary; the Exceptional Access Program via the SADIE portal considers it case-by-case. Psilocybin is not on ODB, and there is no Ontario public-funding precedent for psilocybin comparable to the individual physician-billing precedent reported in Quebec.

Where can I get help finding a Toronto psychedelic-assisted therapy clinician?

TheraPsil maintains a directory of Canadian clinicians trained in supervised psychedelic-assisted therapy. ATMA CENA's information call can orient you to GTA access, including the member-clinic network and the CoCare pathway for keeping your existing therapist. MAPS Canada supports MDMA-assisted therapy advocacy and education.

Compliance disclaimer

Ketamine is approved by Health Canada as an anaesthetic. Use for depression, anxiety, PTSD, and other mental-health indications is off-label, regulated by provincial medical regulators, including the College of Physicians and Surgeons of Ontario (CPSO). Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression in adults aged 18 to 64 as of May 2020 and is not approved for PTSD. Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act (Schedule III and Schedule I respectively); patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada, on a case-by-case basis, and approval is not guaranteed. Access is primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness (psilocybin) or PTSD (MDMA). Coverage decisions are made by the relevant insurer or board on a case-by-case basis; ATMA CENA supports the application and does not guarantee an outcome. Nothing in this article should be construed as a clinical recommendation for a specific individual.

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

Sources

1. ATMA CENA, Information Call: https://atmacena.com/information-call/
2. ATMA CENA, CoCare: https://atmacena.com/cocare/
3. ATMA CENA, Member Clinics: https://atmacena.com/member-clinics/
4. CPSO, Out-of-Hospital Premises Inspection Program: https://www.cpso.on.ca/physicians/your-practice/accreditation-programs/out-of-hospital-premises-inspection-program
5. WSIB Ontario, Ketamine and Esketamine Formulary Decision: https://www.wsib.ca/en/drug-formulary-listing-decision-ketamine-and-esketamine
6. WSIB Ontario, PTSD First Responders Policy: https://www.wsib.ca/en/operational-policy-manual/posttraumatic-stress-disorder-first-responders-and-other-designated
7. Ontario News Release, Working for Workers Five Act, 2024 (Bill 190): https://news.ontario.ca/en/release/36382/ontario-passes-legislation-to-support-first-responders-with-ptsd
8. Health Canada DPD, Spravato: https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
9. Health Canada, Requests for case-by-case access to psychedelic-assisted psychotherapy: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
10. Veterans Affairs Canada, Mental Health Benefits: https://www.veterans.gc.ca/en/financial-programs-and-services/medical-costs/coverage-services-prescriptions-and-devices/mental-health-benefits
11. Ontario Drug Benefit / Exceptional Access Program: https://www.ontario.ca/page/exceptional-access-program
12. TheraPsil: https://therapsil.ca/

Related articles

• What Is Psychedelic-Assisted Therapy?
• Ketamine Therapy Cost in Canada
• CoCare Model
• Member Clinics